Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain

dc.contributor.authorQuero Ramos, Maria
dc.contributor.authorDraibe, Juliana
dc.contributor.authorSolanich, Xavier
dc.contributor.authorRama, Inés
dc.contributor.authorGomà, Montse
dc.contributor.authorMartinez Valenzuela, Laura
dc.contributor.authorFulladosa, Xavier
dc.contributor.authorCruzado, Josep Ma.
dc.contributor.authorTorras, Joan
dc.date.accessioned2021-02-12T11:02:43Z
dc.date.available2021-02-12T11:02:43Z
dc.date.issued2019
dc.date.updated2021-02-12T11:02:43Z
dc.description.abstractBackground. Immunoglobulin G4-related disease (IgG4-RD) is a fibro-inflammatory, immune-mediated disorder, which characteristically affects the glandular tissue but has the potential to affect any organ. Methods. We retrospectively reviewed clinical, laboratory, histological characteristics and treatment response during 12 months of follow-up of a cohort of patients with IgG4-RD diagnosed at a tertiary public hospital. Disease activity was assessed by means of the IgG4-RD responder index (IgG4-RD RI). Results. In all, 15 patients have been diagnosed at our Institution and herein studied (80% men), with a median age of 60.7 years and a mean affectation of 2.8 organs per patient. We identified six patients with definitive diagnosis and nine with possible IgG4-RD, according to the Japanese diagnostic algorithm. IgG4-RD RI decreased from a median of 11.3 at baseline to 4.0 after 6 months and 6.2 after 12 months. Relapse occurred in five patients and was associated with lower cumulative steroid doses. Five patients (33.3%) required additional immunosuppressive (IS) drugs. Five adverse events were seen during follow-up: three infections, one deep vein thrombosis and one gastrointestinal bleeding. One patient died of pneumonia. Conclusions. IgG4-RD is an inflammatory disease that can affect any organ. Glucocorticoids were an effective first line of treatment; however, this treatment is associated with important adverse events and relapses occurred in patients with low cumulative doses. As an alternative, IS treatment with rituximab could be an interesting option in those patients.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701192
dc.identifier.issn2048-8505
dc.identifier.pmid31807295
dc.identifier.urihttps://hdl.handle.net/2445/173915
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1093/ckj/sfz031
dc.relation.ispartofClinical Kidney Journal, 2019, vol. 12, num. 6, p. 829-835
dc.relation.urihttps://doi.org/10.1093/ckj/sfz031
dc.rightscc-by-nc (c) Quero, Maria et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationGlucocorticoides
dc.subject.classificationImmunoglobulina G
dc.subject.classificationHospitals universitaris
dc.subject.classificationEspanya
dc.subject.otherGlucocorticoids
dc.subject.otherImmunoglobulin G
dc.subject.otherUniversity hospitals
dc.subject.otherSpain
dc.titleClinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
701192.pdf
Mida:
696.12 KB
Format:
Adobe Portable Document Format